Atossa Genetics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.8102
- Today's High:
- $0.8639
- Open Price:
- $0.851
- 52W Low:
- $0.5
- 52W High:
- $1.36
- Prev. Close:
- $0.86
- Volume:
- 259631
Company Statistics
- Market Cap.:
- $116.94 million
- Book Value:
- 0.89
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -14.8%
- Return on Equity TTM:
- -22.91%
Company Profile
Atossa Genetics Inc had its IPO on 2012-11-08 under the ticker symbol ATOS.
The company operates in the Healthcare sector and Biotechnology industry. Atossa Genetics Inc has a staff strength of 11 employees.
Stock update
Shares of Atossa Genetics Inc opened at $0.85 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.81 - $0.86, and closed at $0.82.
This is a -4.65% slip from the previous day's closing price.
A total volume of 259,631 shares were traded at the close of the day’s session.
In the last one week, shares of Atossa Genetics Inc have increased by +2.5%.
Atossa Genetics Inc's Key Ratios
Atossa Genetics Inc has a market cap of $116.94 million, indicating a price to book ratio of 0.6275 and a price to sales ratio of 0.
In the last 12-months Atossa Genetics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-30033000. The EBITDA ratio measures Atossa Genetics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Atossa Genetics Inc’s operating margin was 0% while its return on assets stood at -14.8% with a return of equity of -22.91%.
In Q1, Atossa Genetics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Atossa Genetics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.22 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Atossa Genetics Inc’s profitability.
Atossa Genetics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 2.5568. Its price to sales ratio in the trailing 12-months stood at 0.
Atossa Genetics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $116.20 million
- Total Liabilities
- $2.94 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Atossa Genetics Inc ended 2024 with $116.20 million in total assets and $0 in total liabilities. Its intangible assets were valued at $116.20 million while shareholder equity stood at $113.26 million.
Atossa Genetics Inc ended 2024 with $0 in deferred long-term liabilities, $2.94 million in other current liabilities, 22792000.00 in common stock, $-162475000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $103.87 million and cash and short-term investments were $103.87 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Atossa Genetics Inc’s total current assets stands at $110.87 million while long-term investments were $4.70 million and short-term investments were $0. Its net receivables were $738000.00 compared to accounts payable of $1.44 million and inventory worth $0.
In 2024, Atossa Genetics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Atossa Genetics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.82
- 52-Week High
- $1.36
- 52-Week Low
- $0.5
- Analyst Target Price
- $4.63
Atossa Genetics Inc stock is currently trading at $0.82 per share. It touched a 52-week high of $1.36 and a 52-week low of $1.36. Analysts tracking the stock have a 12-month average target price of $4.63.
Its 50-day moving average was $1.02 and 200-day moving average was $0.82 The short ratio stood at 24.86 indicating a short percent outstanding of 0%.
Around 4.1% of the company’s stock are held by insiders while 2066.3% are held by institutions.
Frequently Asked Questions About Atossa Genetics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company’s lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.